NanoViricides Inc. (NNVC): If NNVC was having a problem with reprod...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Monday, 12/05/2016 12:12:23 PM

Monday, December 05, 2016 12:12:23 PM

If NNVC was having a problem with reproducibility, would they be able to send HerpeCide drug(s) to multiple labs and get the same results?

How much material was sent to each lab? Could it have all been from a single batch?

Keep Last Read

Next 10 Prev Next

Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM

InvestorsHub NewsWire

Only $200 per official company press release!